Bellus Health has reported positive results from the Phase I study evaluating NRM8499, a prodrug of tramiprosate, intended for the treatment of Alzheimer’s disease.
The randomised, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetic profile of NRM8499 compared to tramiprosate in 67 healthy subjects.
The study results showed that NRM8499 was safe and well tolerated at the intended therapeutic dose.
In addition, gastrointestinal ability and pharmacokinetic profile of tramiprosate were meaningfully improved with the administration of NRM8499, compared to an equal dose of tramiprosate.
Bellus Health president and chief executive officer Roberto Bellini said the company is pleased with the results of the study.
“The results show a solid potential for pursuing NRM8499 for the treatment of Alzheimer’s disease,” Bellini added.
